Price$4.70-0.01 (-0.21%)
02:00 PM07:45 PM
News · 26 weeks32+67%
2025-12-072026-05-31
Mix2290d
- Insider11(50%)
- Other6(27%)
- SEC Filings3(14%)
- Earnings2(9%)
Latest news
25 items- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the successful completion of its New Drug Application ("NDA") submission on a rolling review basis to the U.S. Food and Drug Administration ("FDA") for D-PLEX100, the Company's lead product candidate for the prevention of surgical site
- PRPolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor ConferencePETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN. Investors interested in meeting with PolyPid should contact their Craig Hallum representative directly. About PolyPidPolyPid Ltd. (NASDAQ:PYPD) is an innovative biopharmaceutical company dedicated to elevating tre
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Provides Corporate Update and Reports First Quarter 2026 Financial ResultsInitiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three months ended March 31, 2026. Recent Corporate Highlights: Initiated NDA Submission to the FDA under Rolling Review: On March 30, 2026, the Company initiated a New Drug Ap
- PRPolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its first quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes bef
- PRPolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual MeetingAnalysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California. The presentation will focus on a detailed analysis of th
- PRPolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company will present new pharmacokinetic data from the Phase 3 SHIELD II trial evaluating D-PLEX₁₀₀ at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 (formerly known as ECCMID), the world's leading congress for clinical microbiology and infectious diseases, taking place on April 17-21, 2026, in Munich, Germany. The abstract titled "Pharmacokinetics of l
- INSIDERSEC Form 3 filed by new insider Jacobovitz Yitzchak Shlomo3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stein Robert Benjamin3 - PolyPid Ltd. (0001611842) (Issuer)
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDAPolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it has initiated a New Drug Application ("NDA") submission to the U.S. Food and Drug Administration (the "FDA") for D-PLEX₁₀₀ for the prevention of surgical site infections ("SSIs") in patients undergoing colorectal surgery. The NDA is being submitted
- INSIDERSEC Form 3 filed by new insider Warshavsky Ori3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dror-Darwish Nir3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Missulawin Jonathan3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Barenholz Yechezkel3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Benamram Joseph3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Story Brooke3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Krinsky Itzhak3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Akselbrad Dikla Czaczkes3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hazan Dalit Fellous3 - PolyPid Ltd. (0001611842) (Issuer)
- PRPolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug ApplicationFDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration (FDA) has granted a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of approximately $4.3 million for the New Drug Application (NDA) for D-PLEX₁₀₀, the Company's lead product candidate for th
- SECSEC Form 20-F filed by PolyPid Ltd.20-F - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Announces Participation in Upcoming Investor ConferencesPETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026. Citizens 2026 Life Sciences Conference Date: March 10, 2026 at 1:40 pm ETLocation: Eden Roc Miami Beach, Miami Beach, FLFormat: Fireside chatWebcast Signup: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/bygPbooQTs4VTXiUdoDYrb Investors who wish to meet with PolyPid management should contact their Citiz
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
PYPD FAQ
7 questionsWhat does PolyPid Ltd. do?
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Where does PYPD stock trade?
PolyPid Ltd. (PYPD) is listed on NASDAQ.What sector and industry is PYPD in?
PolyPid Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PolyPid Ltd. go public?
PolyPid Ltd. (PYPD) completed its IPO in 2020.What are analysts saying about PYPD?
PolyPid Ltd. has had 6 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $900.00 price target on 2025-06-05. Recent price targets range from $900.00 to $2400.00.What companies are similar to PYPD?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PYPD side-by-side with any of them on Quantisnow.How can I track PYPD on Quantisnow?
Quantisnow aggregates PolyPid Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PYPD to receive live email and push alerts on every new disclosure.